Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma

Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma

Abstract Background Checkpoint inhibitors (CPI) have revolutionized the treatment of metastatic melanoma, but most patients treated with CPI eventually develop progressive disease. Local therapy including surgery, ablation or stereotactic body radiotherapy (SBRT) may be useful to manage limited prog...

Full description

Bibliographic Details
Main Authors: Nicholas D. Klemen, Melinda Wang, Paul L. Feingold, Kirsten Cooper, Sabrina N. Pavri, Dale Han, Frank C. Detterbeck, Daniel J. Boffa, Sajid A. Khan, Kelly Olino, James Clune, Stephan Ariyan, Ronald R. Salem, Sarah A. Weiss, Harriet M. Kluger, Mario Sznol, Charles Cha
Format: Article
Language:English
Published: BMJ Publishing Group 2019-07-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Melanoma
Immunotherapy
Metastasectomy
Local therapy
Checkpoint inhibitors
Checkpoint blockade
Online Access:http://link.springer.com/article/10.1186/s40425-019-0672-3

Internet

http://link.springer.com/article/10.1186/s40425-019-0672-3

Similar Items